Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorBamias, A.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKalofonos, C.en
dc.contributor.authorTimotheadou, N.en
dc.contributor.authorSiafaka, V.en
dc.contributor.authorVlahou, I.en
dc.contributor.authorJaninis, D.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T18:56:43Z
dc.date.available2015-11-24T18:56:43Z
dc.identifier.issn0030-2414-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19082
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnemia, Hypochromic/chemically induced/*prevention & controlen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverseen
dc.subjecteffectsen
dc.subjectBlood Transfusionen
dc.subjectErythropoietin/administration & dosage/*therapeutic useen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/*drug therapyen
dc.subjectOrganoplatinum Compounds/administration & dosage/*adverse effectsen
dc.subjectPrognosisen
dc.subjectProspective Studiesen
dc.subjectQuality of Lifeen
dc.subjectRecombinant Proteinsen
dc.subjectRisk Factorsen
dc.subjectTreatment Outcomeen
dc.titlePrevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Groupen
heal.abstractOBJECTIVES: Platinum compounds are commonly associated with significant anemia. Erythropoietin administration has been found effective in correcting anemia in patients with solid tumors receiving chemotherapy. We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin <10 g/dl) in patients with solid tumors receiving platinum-based chemotherapy. METHODS: One hundred forty-four patients with hemoglobin <13 g/dl were included in this study (72 in each arm). Patients in the treatment arm received 10,000 U of recombinant human erythropoietin (rHuEPO) thrice weekly s.c. during platinum-based chemotherapy, while patients in the control arm received no treatment. RESULTS: All patients were evaluable for efficacy. Transfusions were reduced by the administration of rHuEPO (15.3 vs. 33.3%, p = 0.019), and fewer patients developed significant anemia (16.6 vs. 45.8%, p < 0.0001). Subgroup analysis showed that patients with observed to predicted (O/P) serum erythropoietin levels <or=0.9 and responders to chemotherapy benefited from erythropoietin administration in contrast to patients with O/P >0.9 or non-responders. CONCLUSIONS: rHuEPO at a dose of 10,000 U thrice weekly prevents transfusions and development of significant anemia in patients with solid tumors receiving platinum-based chemotherapy.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1159/000067766-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12566906-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000067766&Ausgabe=228855&ProduktNr=223857&filename=000067766.pdf-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2003-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ